

Update on Voluntary Escrow for Minor Vendor Options

Medical technology company, **HeraMED Limited (ASX:HMD)** (“HeraMED” or the “Company”) wishes to inform investors of an update to previously announced voluntary escrow arrangements in relation to the 2,743,655 Unlisted options expiring 5/12/21 at an exercise price of AU\$0.00002 per share.

The Company refers to its initial public offering and in particular, Section 3.11 of its Supplementary Prospectus dated 23 November 2018 which had the effect of inserting Section 7.14 into its Prospectus dated 15 October 2018 (together the “Prospectus”). In that Prospectus at Section 7.14, the Company referred to various shares and options, specifically those held by Altshuler Shaham Trusts Ltd (“Trustee”) as trustee for the Minor Vendors (as defined in the Prospectus), as being subject to a voluntary escrow period of 12 months, that was in addition to the 12 month escrow imposed on those securities by ASX.

Following the Company announcement of 20 November 2019 and in consultation with Trustee, the Company has identified that it was never the intention that those options would be subject to any additional 12 months escrow and that it was an oversight that those options were referred to in the Prospectus as being subject to the additional voluntary escrow.

The Company now wishes to confirm that no voluntary escrow applies to those options.

This announcement has been approved by the Board of HeraMED Limited.

-ENDS-

HeraMED Limited
CEO and Co-Founder
David Groberman
M: +972-52-6991188
E: david@hera-med.com

Company Secretary
Stephen Buckley
T: +61 (0) 8 6189 1155
E: stephen@hera-med.com

About HeraMED Limited (ASX:HMD):

HeraMED is an innovative medical Data and Technology company leading the digital transformation of prenatal care. HeraMED utilises the digital health ecosystem including clinical home monitoring devices, cloud computing, artificial intelligence, big data and digital social networking to reshape the Doctor/Patient relationship. The Company is revolutionising the pregnancy experience by empowering personalised, continuous and proactive home monitoring, to deliver better care at a lower cost. Keeping pregnant mothers engaged, informed and well-supported provides reassurance and peace of mind while allowing the healthcare providers to work at their highest levels of ability and enabling early detection of potential risks.